Previous 10 | Next 10 |
home / stock / dskyf / dskyf news
2024-04-02 16:39:37 ET Summary After a forgettable last year, Merck & Co., Inc.'s stock price is up 20% YTD, supported by approvals, a positive outlook for 2024, and an attractive forward P/E. Keytruda, the company's top-selling treatment, received approval from the European C...
2024-04-02 08:16:01 ET AstraZeneca ( NASDAQ: AZN ) and Daiichi Sankyo’s ( OTCPK:DSNKY ) ( OTCPK:DSKYF ) biologics license application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the U.S. for patients with previously treated metastatic HR-posit...
2024-02-19 07:36:17 ET Read the full article on Seeking Alpha For further details see: Daiichi Sankyo-AstraZeneca gets BLA approved for lung cancer therapy in the U.S.
2024-02-04 12:00:49 ET More on AbbVie, Johnson & Johnson, etc. AbbVie Inc. (ABBV) Q4 2023 Earnings Call Transcript Merck & Co., Inc. 2023 Q4 - Results - Earnings Call Presentation Merck & Co., Inc. (MRK) Q4 2023 Earnings Call Transcript AbbVie cit...
2024-02-01 21:45:05 ET Daiichi Sankyo Company, Limited (DSKYF) Q3 2023 Earnings Conference Call January 31, 2024, 02:00 AM ET Company Participants Koji Ogawa - Head of Global Corporate Planning & Management, CFO Wataru Takasaki - Head of Japan R&D Confe...
2024-02-01 14:27:44 ET More on Daiichi Sankyo Daiichi Sankyo Company, Limited 2023 Q3 - Results - Earnings Call Presentation AstraZeneca/ Daiichi win FDA priority review for Enhertu label expansion Pfizer faces setback in Enhertu patent dispute with Daiichi H...
2024-02-01 07:28:53 ET More on Merck Merck: Big Pharma Looks Stronger Than Ever Ahead Of 2023 Earnings Merck: Set To Keep Soaring Post Q4 Release Merck & Co., Inc. (MRK) JPMorgan 42nd Annual Healthcare Conference (Slides) Merck Non-GAAP EPS of $0.03 beats...
2024-01-29 06:46:23 ET More on AstraZeneca Why AstraZeneca's Gracell Biotechnologies Acquisition Is A Win-Win AstraZeneca: A $1.1B Shot In The Arm From Icosavax Acquisition AstraZeneca Is Feeling The Weight Of The Market In 2023 AstraZeneca launches asthma re...
2024-01-22 13:11:37 ET More on Gilead Sciences Gilead Sciences, Inc. (GILD) JPMorgan 42nd Annual Healthcare Conference (Transcript) Gilead's Dividend Growth Potential Looks Phenomenal Without A Clear Growth Path, Gilead Sciences Is A Hold Biggest stock movers...
2024-01-21 09:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Global growth equities...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Company Name:
DSKYF Stock Symbol:
OTCMKTS Market:
Publication highlights Europe -specific one-year follow-up findings for atrial fibrillation (AF) patients in routine clinical practice, in which, rates of stroke, systemic embolism, and major bleeding are considered by the authors to be low in edoxaban treated patients [1] Findings...
· Results published in the European Heart Journal – Cardiovascular Pharmacotherapy , showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 clinical trial [1] · Study reports LIXIANA outcomes from one of the largest observational ...
- ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based duration of ASA for at least one month) in AF patients following stent placement - ...